Sodium gluconate

CAS No. 527-07-1

Sodium gluconate( —— )

Catalog No. M14868 CAS No. 527-07-1

Sodium gluconate is a corrosion and scale inhibitor of ordinary steel in simulated cooling water.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 31 In Stock
100MG 45 In Stock
200MG 61 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Sodium gluconate
  • Note
    Research use only, not for human use.
  • Brief Description
    Sodium gluconate is a corrosion and scale inhibitor of ordinary steel in simulated cooling water.
  • Description
    Sodium gluconate is a corrosion and scale inhibitor of ordinary steel in simulated cooling water.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    527-07-1
  • Formula Weight
    218.14
  • Molecular Formula
    C6H11NaO7
  • Purity
    >98% (HPLC)
  • Solubility
    Water: 44 mg/mL (201.7 mM)
  • SMILES
    C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Na+]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ramachandran S, et al. Food Technol. Biotechnol, 2006, 44(2) 185-195.
molnova catalog
related products
  • Dehydroeburicoic aci...

    Dehydroeburicoic acid monoacetate is a triterpenoid of lanolin isolated from Wolfiporia cocos.

  • 1H-1-ethyl Candesart...

    1H-1-ethyl Candesartan Cilexetil is a process-related impurity in the bulk synthesis of candesartan cilexetil, which is a potent, long-acting and selective angiotensin II type 1 receptor (AT1) antagonist.

  • Oxindole

    Oxindole is an aromatic heterocyclic building block.?2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.